

---

CURRICULUM VITAE  
**David L. DeRemer, Pharm.D FCCP BCOP**  
September 2017

---

**PERSONAL INFORMATION**

Office Address: University of Florida College of Pharmacy  
Department of Pharmacotherapy and Translational Research  
HPNP 2302  
Gainesville, FL 32610

Email: [dderemer@cop.ufl.edu](mailto:dderemer@cop.ufl.edu)

Telephone: Office: 352-273-8245  
Fax: 352-273-6485

**EDUCATION**

1992-1996 B.S., Biology  
University of Kentucky College of Arts and Sciences

1998-2002 Doctor of Pharmacy  
University of Kentucky College of Pharmacy

**POSTDOCTORAL TRAINING**

2002-2003 Pharmacy Practice Residency (ASHP-Accredited)  
University of Kentucky Chandler Medical Center  
Lexington, KY  
Director: Kelly Smith Pharm.D., BCPS, FASHP, FCCP

2003-2004 Hematology-Oncology Residency (ASHP-Accredited)  
University of Kentucky Chandler Medical Center  
Lexington, KY  
Director: Val Adams Pharm.D., FCCP, BCOP

2004-2005 Oncology Postdoctoral Fellowship  
Drug Discovery/Development  
University of Kentucky Chandler Medical Center  
Director: Val Adams Pharm.D., FCCP, BCOP

---

## **ACADEMIC RANK AND APPOINTMENTS**

9/2006-6/2012	Clinical Assistant Professor University of Georgia College of Pharmacy Department of Clinical and Administrative Pharmacy Clinical and Experimental Therapeutics (CET) Program Augusta, GA
7/2012- 8/2017	Clinical Associate Professor University of Georgia College of Pharmacy
7/2013- 8/2017	Adjunct Clinical Associate Professor Medical College of Georgia Department of Medicine, Section of Hematology/Oncology Augusta, GA
9/2017- current	Clinical Associate Professor University of Florida College of Pharmacy Department of Pharmacotherapy and Translational Research

## **PROFESSIONAL LICENSURE AND BOARD CERTIFICATION**

2002- current	Kentucky Pharmacy Licensure (#012403)
2005- current	Georgia Pharmacy Licensure (#022799)
2006- current	Board of Pharmaceutical Specialties Board Certified Oncology Pharmacist (#506006838) Recertified by CE (2012)

## **PROFESSIONAL EXPERIENCE**

1996-1998	Senior Lab Technician University of Kentucky College of Medicine Department of Microbiology & Immunology Jesse Sicken, Ph.D. Laboratory
1999-2002	CVS Pharmacy Intern Lexington, KY
2004-2005	Hematology/Oncology PRN Pharmacist

---

University of Kentucky Markey Cancer Center  
Lexington, KY

2005-2006  
Hematology/Oncology Clinical Specialist  
Bone Marrow Transplant/Oncology Clinical Specialist  
Medical College of Georgia (MCG Inc.)  
Augusta, GA

2006- 2013  
Inpatient Hematology/Oncology Clinical Specialist  
Inpatient Bone Marrow Transplant/Oncology Clinical Specialist  
Georgia Regents University Medical Center  
(Formerly Georgia Health Sciences University and MCG Health)  
Augusta, GA

2013- 2017  
Outpatient BMT/Hematological Malignancies Clinical Specialist  
Georgia Cancer Center  
Augusta, GA

2017- present  
Assistant Director of the Experimental Therapeutics Incubator  
University of Florida Health Cancer Center (UFHCC)  
Gainesville, FL

### **TEACHING EXPERIENCE**

University of Georgia College of Pharmacy

*Pharm.D. Curriculum*

<b>Semester</b>	<b>Course</b>	<b>Format</b>	<b>Hours</b>
Spring 2017	PHRM 5210- Integrated Patient Cases	Cases, simulated EMR	2 contact hours
Spring 2017	PHRM 5870 Pharmacotherapy II	Video, interactive cases, didactic	10 contact hours Course coordinator
Spring 2017	PHRM 4040 Essentials of Pharmacy Practice – IV	Skills Lab (Hazardous Agents)	2 contact hours
Spring 2017	PHRM 3040 Essentials of Pharmacy Practice - II	Small group recitation	8 contact hours
Fall 2016	PHRM 3030 Essentials of Pharmacy Practice - I	Small group recitation	8 contact hours

Spring 2016	PHRM 3520 Interpreting Clinical Lab Tests	Didactic	1 contact hour
Spring 2016	PHRM 5870 Pharmacotherapy II	Video, interactive cases, didactic	3 contact hours
Fall 2015	PHRM 5210 Resident Rounds	Small Group, didactic	12 contact hours
Fall 2015	PHRM 5210 Insights into Clinical Practice	Small Group, Interactive cases	2 contact hours
Spring 2015	PHRM 5870 Pharmacotherapy II	Video, interactive cases, small group	2 contact hours
Fall 2014	PHRM 5190 Anticancer Therapeutics	Didactic	5 contact hours
Spring 2014	PHRM 5980 Pharmacotherapy II	Video, interactive cases, small group	2 contact hours
Fall 2013	PHRM 5190 Anticancer Therapeutics	Didactic	10 contact hours
Spring 2013	PHRM 5870 Pharmacotherapy II	Videos, interactive cases	7 contact hours
Spring 2013	PHRM 5920	Seminar advising	3-5 contact hours
Fall 2012	PHRM 4190 Cancer and Chemotherapy	Didactic	14 contact hours Course co-coordinator
Spring 2012	PHRM 5870 Pharmacotherapy II	Videos, interactive cases	7 contact hours
Spring 2012	PHRM 5920	Seminar advising	3-5 contact hours
Fall 2011	PHRM 4190 Cancer and Chemotherapy (Co- ordinator)	Didactic	14 contact hours
Spring 2011	PHRM 5870 Pharmacotherapy II	Videos, interactive cases	7 contact hours
Spring 2011	PHRM 5210- Landmark Clinical Studies in Oncology and Clinical Applications Elective (Co-coordinator)	Seminars, interactive cases, experiential	14 contact hours
Spring 2011	PHRM 5920	Seminar advising	3-5 contact hours
Fall 2010	PHRM 4190 Cancer and Chemotherapy (Co- ordinator)	Didactic	14 contact hours
Spring 2010	PHRM 5210- Landmark Clinical Studies in Oncology and Clinical	Seminars, interactive cases, experiential	14 contact hours

	Applications Elective (Co-coordinator)		
Fall 2009	PHRM 4190 Cancer and Chemotherapy (Co- coordinator)	Didactic	14 contact hours
Spring 2009	PHRM 5870 Pharmacotherapy II	Didactic, videos	8 contact hours
Fall 2008	PHRM 5860 Pharmacotherapy I	Didactic, videos	8 contact hours
Fall 2008	PHRM 5140- Clinical Skills Lab (Co- Coordinator)	Facilitated labs with OSCEs	12 contact hours
Spring 2008	PHRM 5870 Pharmacotherapy II	Didactic, videos	8 contact hours
Spring 2008	PHRM 5210- Clinical Oncology Elective	Interactive cases, seminars, experiential	12 contact hours
Fall 2007	PHRM 3800 Clinical Applications I	Patient Interviews	8 contact hours
Fall 2007	PHRM 5860 Pharmacotherapy I	Didactic, videos	8 contact hours
Fall 2007	PHRM 5140- Clinical Skills Lab (Co- Coordinator)	Facilitated labs with OSCEs	12 contact hours
Spring 2007	PHRM 5870 Pharmacotherapy II	Didactic, videos	8 contact hours
Spring 2007	PHRM 5210- Clinical Oncology Elective	Interactive cases, seminars, experiential	12 contact hours
Fall 2006	PHRM 3800 Clinical Applications I	Patient Interviews	8 contact hours

### *Experiential Experiences*

<b>Year</b>	<b>Rotations</b>	<b>Practice Site (s)</b>	<b>Students- hours</b>
2007- 2017	5901-5908 (APPE)	<ul style="list-style-type: none"> <li>• Inpatient Hematology/Oncology</li> <li>• BMT</li> <li>• Outpatient Oncology</li> </ul>	8-10 students per year 150- 200 contact hours per rotation
2012- 2017	IPPE	<ul style="list-style-type: none"> <li>• Oncology</li> </ul>	8-12 students per year

### *Resident Graduate Curriculum*

<b>Year</b>	<b>Rotations</b>	<b>Format</b>	<b>Graduate students- hours</b>
2011-2017	PHRM 7210 Advanced Pharmacy Care	Small group discussion	5-7 students- 5 contact hours/year

2011-2017 (Fall semesters)	PHRM 7810 Pharmacy Care	Direct precepting	1-2 students- > 100 contact hours
2011-2017	PHRM 7910 Adv Pharmacy Care	Direct precepting	>100 contact hours
2011- 2017	PHRM 7830 Residency Research	Research advising	1-2 students- > 100 contact hours
2011- 2017	PHRM 7840 Teaching Pharmacy Practice	Advising	1 students -> 10 contact hours
2011- 2017	PHRM 7940 Teaching Pharmacy Practice PGY2	Advising	1-2 students -> 10 contact hours
2012-2013	PHRM 7210 Special Topics PGY2 Oncology Residents	Interactive cases	10 contact hours

Medical College of Georgia College of Allied Health- Physician Assistant Program

2009-2015                      *Chemotherapy 101*  
*Chemotherapy Induced Nausea-Vomiting*  
Format: Didactic lectures

Medical College of Georgia College of Nursing

2008-2012                      NSG 7430 - Pharmacology for Advanced Practice Nurses  
*Pain Management* (3 contact hours annually)  
*Adjuvant Treatments in Cancer* (3 contact hours annually)

University of Kentucky College of Pharmacy

Spring 2004                      Integrated Applied Therapeutics II (PHR 963)  
(2 contact hours)

Fall 2004                         Integrated Applied Therapeutics I (PHR 962)  
(2 contact hours)

Fall 2003                         Contemporary Aspects of Pharmacy Practice (PHR 939)  
(8 contact hours)

Spring 2002                      Contemporary Aspects of Pharmacy Practice (PHR 919)  
(8 contact hours)

---

University of Kentucky College of Allied Health Sciences-Physician Assistant

Spring 2003

Pharmacology Course  
*Immunomodulating Agents*  
*Antineoplastic Agents*  
(2 contact hours)

**POSTGRADUATE TRAINEES**

**PGY2 Oncology Pharmacy Residency Program Director**

<b>Year</b>	<b>Graduate Resident</b>	<b>Current Position</b>
2011-2012	Katerina Katsanevas Butler, Pharm.D BCOP	Oncology Clinical Specialist VA Medical Center Salt Lake City, UT
2012-2013	Stephen Clark, Pharm.D. BCOP	BMT Clinical Specialist University of North Carolina Chapel Hill, NC
2012-2013	Alison Steinbach, Pharm.D	Outpatient Clinical Specialist West Penn Allegheny Hospital Pittsburgh, PA
2013-2014	Megan Hartranft, Pharm.D. BCPS, BCOP	Clinical Assistant Professor Rosalind Franklin College of Pharmacy Rush Cancer Center Chicago, IL
2014-2015	Sarah Evans, Pharm.D. BCOP	Outpatient Clinical Specialist The Ohio State Medical Center James Cancer Center Columbus, OH
2015- 2016	Julianne Orr, Pharm.D.	Outpatient Clinical Specialist Indiana Health Indianapolis, IN
2016-2017	Ben Andrick, Pharm.D.	BMT Clinical Specialist Geisinger Health System Danville, PA
7/2017-8/2017	Morgan Gwynn, Pharm.D.	PGY2 Resident at AU/UGA

**UGA Clinical and Experimental Therapeutics (CET) Clinical Program Training**

<b>Year</b>	<b>Graduate Student</b>	<b>Rotation</b>
2010	Belal Al-Husein, M.S.	Inpatient Oncology
2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Inpatient Oncology
2014	Harika Sabbineni, B.Pharm.	Outpatient BMT

---

**UGA Clinical and Experimental Therapeutics Dissertation Committee Member**

<b>Year</b>	<b>Graduate Student</b>	<b>Thesis Title</b>
2010-2011	Belal Al-Husein, M.S.	Molecular mechanisms regulating simvastatin-mediated inhibition of prostate cancer cellular functions <i>in vitro</i> and tumor growth <i>in vivo</i>
2011-2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Role of Akt in myofibroblast differentiation leading to pulmonary vascular remodeling and idiopathic pulmonary fibrosis
2015-current	Abdul M. Alwhaibi, Pharm.D.	In-progress

**PGY1 Pharmacy Residency Precepting**

<b>Year</b>	<b>Graduate Resident</b>	<b>Rotation</b>
2010-2011	Katerina Katsanevas, Pharm.D. BCOP	Inpatient hematology/oncology
2009-2010	Karly O'Brien, Pharm.D.	Inpatient hematology/oncology
2009-2010	Ashley Richard, Pharm.D.	Inpatient hematology/oncology
2009-2010	Amber Bradley, Pharm.D. BCOP	Inpatient hematology/oncology
2008-2009	Neha Dosi, Pharm.D.	Inpatient hematology/oncology
2008-2009	Evelina Maciuleviciute, Pharm.D.	Inpatient hematology/oncology
2007-2008	Tim Robinson, Pharm.D. BCPS	Inpatient hematology/oncology
2007-2008	Kinjal Vikal, Pharm.D.	Inpatient hematology/oncology

**CERTIFICATIONS/OTHER TRAINING**

2015	Chairs and Academic Administrators Management Program (CAAMP) Academy for Academic Leadership Atlanta, GA
2014	ACCP Focused Investigator Training (FIT) Program Athens, GA



---

2012	CITI- Collaborative IRB Training Initiative Certification Georgia Health Sciences University Refresher Course Completed (2006, 2009)
2012	CITI Certification for Institutional Review Board Members Georgia Health Sciences University
2007	Biosafety Training Certification Medical College of Georgia
2006	Saf-T-Pak Inc Biological Specimens Certification Recertification (2015- Safe Transports of Biological Substances) Medical College of Georgia
2004	Scholarship of Teaching and Learning Certificate Program University of Kentucky Chandler Medical Center
2003	Navigating the Clinical Research Process Investigator Training University of Kentucky Chandler Medical Center
2003	Advanced Cardiac Life Support Certification University of Kentucky Chandler Medical Center
2002	Adult Immunizations Certification University of Kentucky College of Pharmacy

## **PRESENTATIONS**

### National

1. *Schedule-dependent Synergism and Antagonism between Paclitaxel and Topotecan in Human Ovarian Cancer Cell Lines in vitro*. Scientific Paper Platform Presentation. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting; San Francisco, CA. October 2005
2. *Strategies for Success in Pharmacy Board Certification: A Panel Discussion*. Panel – Smith KM, Canada TW, Divine H, Jennings HR. Presented at the 42<sup>nd</sup> American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting; Las Vegas, NV. December 2, 2007
3. *Hodgkin Lymphoma BCOP Recertification Presentation*. Presented at the 9<sup>th</sup> Annual Hematology Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013.

- 
4. *Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical practice.* Co-presenters- Clark S and Hartranft M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 22, 2013.
  5. *Have you submitted that paper yet? Successfully precepting student and resident research projects.* Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 23, 2013.
  6. *Hodgkin Lymphoma BCOP Recertification Presentation.* Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. October 15, 2013.
  7. *Hodgkin Lymphoma BCOP Recertification Presentation.* Presented at ASHP Annual Meeting Orlando, FL. December 10, 2013.
  8. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcomes and drug response.* The Great Eight Best Paper Presentations Series. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Austin, TX. October 13, 2014
  9. *Hematology/Oncology PRN Focus Session: Confronting the Global Epidemic of Human Papillomavirus (HPV) and Associated Malignancies.* Moderator at Global American College of Clinical Pharmacy (ACCP) Annual Meeting San Francisco, CA. October 19, 2015.
  10. *Recent Advances in the Treatment and Management of Lymphomas.* Presented at HOPA BCOP Updates Course Orlando, FL. July 16, 2016.
  11. *Malignancy in the HIV Patient.* Presented at the ACCP Annual Meeting Hollywood, FL. October 24, 2016.
  12. *Oral Chemotherapy Education.* Presented at the National Community Oncology Dispensing Association (NCODA) Annual Summit Atlanta, GA. October 29, 2016.
  13. *Managing Acute Lymphoblastic Leukemia (ALL): A Review on Diagnosis and Clinical Considerations for the Healthcare Professional.* Webinar provided by Specialty Pharma Education Center, 2016.

#### Regional

1. *The Specific Role of 92kDa Type IV Collagenase in Metastatic Tumor Cells* Howard Hughes Research Award Winners Presentation. Kentucky/Tennessee Academy of Science Joint Meeting Bowling Green, KY. May 1996

- 
2. *Erythropoietin Response in Patients Concurrently Receiving Capecitabine* ACPE accredited continuing education program. Southeastern Residency Conference University of Georgia. Athens, GA. May 2003
  3. *Thymoquinone: Analytical Method and Assay Validation*. Southeastern Residency Conference. ACPE accredited continuing education program. University of Georgia. Athens, GA. May 2004
  4. *Selected Overview of Recently Approved Oncology Agents: Targeting New Molecular Targets* Kentucky Health System Pharmacists (KSHP) Annual Meeting. ACPE accredited continuing education program.. Lexington, KY. September 2004.
  5. *New Oncology Agents*. Georgia Health System Pharmacists (GHSP) Fall Annual Meeting ACPE accredited continuing education program. Helen, GA October 2006.
  6. *The Generational Joust: Strategies for Boomers and GenXers as the Millennials Enter the Profession of Pharmacy*. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL June 2008
  7. *Breast and Gynecological Cancers*. South Carolina Pharmacists Association Summer Meeting ACPE accredited continuing education program. Hilton Head, SC June 2010.
  8. *Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents* Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2012.
  9. *Confronting the Rise of Cancers in the HIV Population*. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2017.

#### State

1. *Angiogenesis: Switching On/Off Molecular Targets for Differing Clinical Outcomes* ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. February 2006.
2. *What's "Hot" in the Treatment of Leukemias*. ACPE accredited continuing education program MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2006.
3. *Perspective of a New Generation Xer Professor- Challenges and Strategies of Teaching the Millennials*. ACPE accredited continuing education program/ MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2007.

- 
4. *Neurotoxicity of Chemotherapeutic Agents*. MCG Neurology Resident Ground Rounds Series Medical College of Georgia, Augusta, GA. February 2008.
  5. *Recent Significant Advances in Oncology*. ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah and Athens, GA. April 2009.
  6. *Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants*. ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. April 2011
  7. *Maintaining the Maintenance: Is this the Future of Cancer Therapy*. ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. October 2012.
  8. *Recent Advances in Cancer Immunotherapy: Developing a Killer Instinct*. ACPE accredited continuing education program. GRU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. September 2014.
  9. *Hematopoietic Growth Factors*. Augusta University Division of Hematology/Oncology Fellows Grand Rounds. February 8, 2017.

#### **PEER-REVIEWED PUBLICATIONS**

1. Sisken J, **DeRemer DL**. Power frequency electromagnetic fields and the capacitative calcium entry system in SV40-transformed Swiss 3T3 cells. *Radiation Research* 2000;153:699.
2. Ustun C, Farrow S, El-Genaidy, **DeRemer D**, Jillella A. A serious complication of allogeneic stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. *Clinical Medicine: Oncology* 2007; 1 91-94
3. Ustun C, Farrow S, **DeRemer D**, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. *Bone Marrow Transplant* 2007 Jun; 39(12):807-8.
4. Ustun C, **DeRemer DL**, Steele J, Forseen C, Fisher JF, Jillella AP. Fatal breakthrough Aspergillus fumigatus and Candida glabrata infections in a leukemia patient on posaconazole prophylaxis. *Int J Antimicrob Agents*. 2008 Oct; 32(4):365-6.
5. Ustun C, Kalla A, Farrow S, **DeRemer DL**, Jillella A. Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. *Am J Hematol*. 2008 Oct; 83(10):825-7

- 
6. **DeRemer DL**, Natarajan K, Ustun C. Nilotinib (Tasigna®): A second generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. *Clin Ther.* 2008 Nov;30(11):1956-75.
  7. Ustun C, **DeRemer DL**, Jillella A, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. *Expert Opinion Investig Drugs* 2009 Oct;18(10):1445-56.
  8. Adams VR, **DeRemer DL**, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM, Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. *Anticancer Res.* 2010 Jul;30(7):2505-12.
  9. Lewis G, Hall P, Eisa N, **DeRemer DL**, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high dose cytarabine consolidations and thus do not require prophylaxis. *Acta Haematologica* 2010 Nov 12;124(4):206-213
  10. Ustun C, Jillella A, Shah R, Sterling K, **DeRemer DL**, et al. Second allogeneic stem cell transplantation from different donor improves severe steroid-resistant gut GVHD. *Bone Marrow Transplant* 2010 Nov;45(11):1658-60
  11. Willis LM, Somanath PR, El-Remessy AB, **DeRemer DL**, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. *Clin Science* 2011 Apr; 120 (8):307-19
  12. **DeRemer DL**, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of chronic myeloid leukemia. *Cancer Manag and Res.* 2011 Mar 10;3:65-78.
  13. Ustun C, **DeRemer DL**, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis. *Leukemia Res.* 2011 Sep;35(9):1143-52
  14. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison, D, Speir E, **DeRemer D**, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma patients treated with novel induction therapies. *Biol Blood Marrow Transplant.* 2012 Jul;18(7):1128-35
  15. Awan F, Kochuparambil ST, **DeRemer D**, et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. *J Oncol* 2012;2012: 931071
  16. Al-Husein B, Abdalla M, Trepte M, **DeRemer DL**, Somanath PR. Anti-angiogenic therapy for cancer: An update. *Pharmacotherapy.* 2012 Dec;32(12):1095-111.

- 
17. **DeRemer DL**, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of platelet recovery (SFPR). *J Oncol Pharm Pract* 2013 Dec;19(4):369-72
  18. Bradley A, Devine M, **DeRemer DL**. Brentuximab vedotin: A novel antibody-drug conjugate. *Am J Health Syst Pharm*. 2013 Apr 1;70(7):589-97
  19. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, **DeRemer D**, Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. *Bone Marrow Transplant* 2013 Oct;48(10):1279-84
  20. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, **DeRemer DL**, Somanath PR. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression *in vitro* and *in vivo*. *Oncotarget* 2014 15;5(3):775-87.
  21. Bradley A, Evans S, **DeRemer DL**, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? *J Oncol Pharm Pract*. 2015 Dec;21(6):425-32.
  22. Clark SM, Clemmons A, Schaack L, Garren J, **DeRemer DL**, Vota V. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. *J Oncol Pharm Pract*. 2016 Jun;22(3):416-22.
  23. Hartranft M, Clemmons A, **DeRemer DL**, Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. *J Oncol Pharm Pract. J Oncol Pharm Pract*. 2017 Jan;23(1):10-17
  24. **DeRemer DL**, Clemmons AB, Orr J, Clark SM, Gandhi A. Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting. *Pharmacotherapy*. 2016 Feb;36(2):218-29.
  25. Mangonkar A, Xu H, Moshin J, Mansour J, Chintalapally R, Keen R, Mondal AK, **DeRemer D**, et al. Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. *J Community Support Oncol*. 2016 Feb;14(2):66-71.
  26. Evans SS, Gandhi AS, Clemmons AB, **DeRemer DL**. Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-Containing regimens in Non-Hodgkin lymphoma. *J Pharm Pract*. 2016 Jul 18. pii: 0897190016659210. [Epub ahead of print]
  27. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, **DeRemer DL**, et al. The importance of research and scholarly activity in pharmacy training. *Pharmacotherapy*. 2016 Dec;36(12):e200-e205.

- 
28. Andrick B, Alwahibi A, **DeRemer DL**, Quershi S, Khan R, Bryan L, Somanath PR, Pantin J. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukemia patients receiving ibrutinib. *Br J Haematol*. 2017 Jul 24 [epub ahead of print]
  29. Gwynn ME, **DeRemer DL**. The emerging role of PD-1/PD-L1 targeting immunotherapy in the treatment of metastatic urothelial carcinoma. *Ann Pharmacother*. 2017 Aug 1 [epub ahead of print]

#### **NON-PEERED REVIEWED**

1. Adams VR, **DeRemer, DL**, Kilbridge JF. Apoptosis: Novel Molecular Targets in Cancer Therapy, Clinical Focus on Bcl-2. *Oncology Special Edition Dec 2004*.
2. **DeRemer DL**. Blincyto® (blinatumomab) for patients with Philadelphia chromosome-negative relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. Submitted to *Pharmacy Practice News* March 2015.
3. **DeRemer DL**. Empowering Community Pharmacists as Health Consultants: Chemotherapy-Induced Nausea and Vomiting. *Inside Patient Care*. December 2015.

#### **BOOK CHAPTERS**

1. Gerson SL, Bhalla KN, Grant S, Natarajan K, Grant S, Creger RJ, **DeRemer D**. *Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies*. In: *Hematology: Basic Principles and Practice* (eds Hoffman R, Silberstein LE, Shattil SJ, et al.) 5th edition. Elsevier, Philadelphia, PA. 2008, p 839-873.
2. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York. 2011 p143 -150.
3. **DeRemer DL**, Manasco KB, Fagan SC. *Research: Becoming a Scholar*. In: Murphy JE (ed) *American College of Clinical Pharmacy Resident Survival Guide*. Lenexa, KS, 2011.
4. **DeRemer DL**. Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat UR (eds): *Chronic Myeloid Leukemia: From Daily Management to Complicated Issues*. New York, NY: Nova Science Publishers; 2014 pp. 251-262.
5. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York. 2015.
6. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 3rd edition. McGraw-Hill., New York. 2017. (Submitted)

---

## **HANDBOOKS**

1. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2004
2. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2005
3. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2007
4. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2008
5. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2009
6. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2010
7. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2011
8. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2012
9. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2013
10. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2014
11. Adams, V.R. **DeRemer DL**, Bernhardt, MB. Guide to Cancer Therapeutic Regimens. McMahon Publishing, New York, NY 2017.



---

## **ABSTRACTS/POSTERS**

1. Liewer SE, Hecht KA, Smith, CA, **DeRemer DL**, Adams VR, et al. Gelclair® for the treatment chemotherapy induced stomatitis in transplant and hematology patients: An interim analysis. *Blood*. 2004 Nov 16;104: 5317
2. Gallt RR, Mattingly CA, **DeRemer DL**, Adams VR. Determination of in vitro growth inhibition by novel farnesyl diphosphate analogues. American College of Clinical Pharmacy (ACCP) Annual Meeting 2005 San Francisco, CA. Abstract #511
3. **DeRemer DL**, Mattingly CA, Adams VR. In vitro interaction between topotecan (TPT) and paclitaxel (PAC) in three human ovarian cancer cell lines. ACCP Annual Meeting 2005 San Francisco, CA. Abstract #245
4. Kendrick A, Lake B, **DeRemer D**, Fain H, Farrow S, Ustun C, and Jillella A. Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation (HSCT). Presented at the 2007 American Colleges of Clinical Pharmacy Annual Meeting Denver, CO; October 15, 2007. Abstract #353.
5. Kendrick A, **DeRemer DL**. Evaluation of institutional BMT program compliance with recommended post-hematopoietic stem cell transplant (HSCT) vaccination guidelines. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007
6. Fussell J, Boyle K, Kuth J, **DeRemer DL**, Ustun C. Review of institutional use of prophylactic voriconazole and posaconazole in patients with hematological malignancies. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007.
7. Stevich B, Mattingly C, **DeRemer DL**, Spielmann P, Adams V. Targeting Ras with false prenyl analogs. Presented at 2008 American Colleges of Clinical Pharmacy (ACCP) Annual Meeting Louisville, KY; October 2008.
8. Carbonell C, **DeRemer DL**. Institutional analysis of rasburicase in the management of tumor lysis syndrome. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.
9. Nestor MA, **DeRemer DL**. Evaluation of outcomes in acute promyelocytic leukemia patients receiving ATRA (All-trans Retinoic Acid). Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008
10. Almeter PJ, Robinson T, **DeRemer DL**. Institutional evaluation of vancomycin in neutropenic patients. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.

- 
11. Maciuleviciute E, Davis W, **DeRemer DL**. Evaluation of hypertension management bevacizumab treated patients. Presented at the 2008 University Health Consortium Pharmacy Council Resident Poster Session, Orlando, FL. December 6, 2008
  12. Graham CR, Butterfield J, **DeRemer DL**. Impact of peptide nucleic acid fluorescence in situ hybridization (PNA FISH)-based identification of Candida species on antifungal utilization. Presented at the 2009 University Health Consortium Pharmacy Council Resident Poster Session, Las Vegas, NV. December 5, 2009
  13. Mebel E, McAllister J, **DeRemer DL**. Evaluation of plerixafor on stem cell collection prior to an autologous hematopoietic stem cell transplant (aHSCT). Presented at 2009 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV. December 2009.
  14. Awan F, **DeRemer D**, Mebel E, et al. Utility of plerixafor in addition to chemotherapy and G-CSF mobilization regimens. Blood (American Society of Hematology (ASH) Annual Meeting) 2010;116: 4443.
  15. Katsanevas K, Ajiboye V, **DeRemer DL**. Evaluation of pegfilgrastim for primary prophylaxis for of neutropenic fever. Presented at the 2010 University Health Consortium Pharmacy Council Resident Poster Session, Anaheim, CA. December 4, 2010
  16. Kochuparambil T, **DeRemer DL**, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented at the 2011 American Society for Blood and Marrow Transplantation (ASBMT) Meeting. Honolulu, HI. February 17-21, 2011
  17. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, **DeRemer DL**. Evaluation of obesity on achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual Meeting 2011 Pittsburgh, PA. Abstract # 448
  18. Morrison DD, Kochuparambil ST, **DeRemer DL**, et al. Clinical Practice Guideline for the treatment of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.
  19. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, **DeRemer D**, et al. Intermediate-versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies – A multicenter analysis. Blood (ASH Annual Meeting Abstracts), Nov 2011;118: 313.

- 
20. Katsanevas K, Al-Husein B, **DeRemer D**, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA) Meeting, Orlando, FL. March 22, 2012.
  21. **DeRemer DL**, Katsanevas K, Forehand C, et al. Successfully integrating translational research into a PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors Conference in Washington, DC. August 17, 2012.
  22. **DeRemer DL**, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
  23. Evans S, **DeRemer D**, Bradley A. Intravenous busulfan pharmacokinetics in conditioning regimens for allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes. Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
  24. Awan F, Kochuparambil ST, Craig M, Cumpston A, Leadmon, S, Watkins K, **DeRemer D**, Pantin J, Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4409
  25. Steinbach A, Goc A, **DeRemer D**, Shenoy S. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis. Presented at the 9<sup>th</sup> Annual HOPA Conference in Los Angeles, GA. March 21, 2013.
  26. Schaack L, Clark SM, Clemmons AB, **DeRemer DL**, Kota V. Characterization of chemotherapy induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP Annual Meeting in Albuquerque, NM. Abs #347
  27. Clark SM, Schaack L, **DeRemer D**, Kota V, Clemmons AB. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl):S287.
  28. Hartranft ME, **DeRemer DL**, Kolhe R, Phillips BG. Investigation of epigenetic modifications in obese and non-obese acute myeloid leukemia patients. Presented at 10<sup>th</sup> Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster #125

- 
29. **DeRemer DL**, Hartranft ME, Mondal A, Kolhe R, Meagher R, Phillips BG. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response. Presented at 2014 ACCP Annual Meeting in Austin, TX. Abs#442.
  30. Evans S, Clemmons AB, Gandhi A, **DeRemer D**. Clinical and economic evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in Non-Hodgkin lymphoma. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Austin, TX. Resident Trainee Poster #32
  31. Orr J, Clemmons AB, Gandhi A, **DeRemer D**. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of CINV in hematology patients receiving highly emetogenic chemotherapy regimens (The FOND-O Study). Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #100
  32. Andrick B, **DeRemer D**, Abdul Sater- H, Bollag R, Pantin J, Shenoy S. Pneumococcal vaccine response in chronic lymphocytic leukemia patients with ibrutinib. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #27
  33. Andrick B, Alwhaibi A, **DeRemer D**, Quershi, Khan R, Shenoy S, Pantin J. Antibody response to pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving ibrutinib. Blood 2016 128:5597.

## **GRANTS**

1. *Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation.* University of Georgia Randy Ellison Cancer Research Grant. Project period 10/06-5/07. (Primary Investigator, 50% effort). Total award \$2000
2. *Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy?* University of Georgia Translational Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5% effort). Total award \$7500
3. *Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis.* Submitted 9/12 for University of Georgia Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award \$10,000
4. *Examining TGF $\beta$  and Integrin  $\alpha$ v $\beta$ 3 Expression in Early and Aggressive Human Prostate and Bladder Cancer Tissues as Biomarkers for early detection and as targets for therapy.* Project

---

period 2013-14. University of Georgia Translational Research Initiative Grant. (Sub-investigator, 5% effort). Total award \$10,000

5. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2014-2015. (PI, 75% effort). Total award \$4,500
6. *Pneumococcal vaccine response in chronic lymphocytic leukemia (CLL) patients receiving ibrutinib.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2015-2016. (PI, 75% effort). Total award \$4,000

### **CLINICAL TRIALS**

1. A Phase IA/II, two-arm, multi-center, open-label, dose escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies. – Role: Institutional Sub-I. 2006-2008.
2. A Phase I dose finding study of the anti-angiogenesis agent, AG-013736 in combinations of paclitaxel/carboplatin, weekly paclitaxel, docetaxel, capecitabine, and gemcitabine/cisplatin in patients with advanced solid tumors. - Role: Institutional Sub-I. 2007.
3. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the FOND-O Study. (NCT02635984)- Investigator Initiated Trial, Role: Institutional Sub-I. 2015-current
4. An open-label study of rovalpituzumab tesirine in subjects with delta-like protein 3-expressing advanced solid tumors. Role: Institutional Sub-I. 2017-current
5. A Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment. Role: Institutional Sub-I. 2017-current
6. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. Role: Institutional Sub-I. 2017-current
7. A Phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors. Role: Institutional Sub-I. 2017-current

---

## **OTHER SCHOLARLY/CREATIVE WORKS**

1. In collaboration, developed – Required competency areas, goals, and objective for PGY2 Oncology Pharmacy Residencies (2017) - <http://www.ashp.org/DocLibrary/Residents/Oncology-Pharmacy-2016.pdf>

## **HONORS AND AWARDS**

2015	Elected to Fellowship in ACCP
2014	ACCP Annual Meeting – Best Paper Award
2014	ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient
2012	Georgia Society of Health-System Pharmacists (GHSP) Outstanding Practitioner of the Year
2005	ACCP Research Travel Award
2003	Clinical Pharmacy Residents Program Educational Grant- Pfizer
2003	University of Kentucky Medical Center Resident of the Month
1996	Howard Hughes Research Institute Research Award

## **ADMINISTRATIVE ACTIVITY/COMMITTEES**

### University of Georgia College of Pharmacy

2016-2017	Academic and Professionalism Committee
2013-2017	Student Wellness Committee
2013-2017	Students Oncological Advocates in Pharmacy (SOAP)- Faculty Advisor
2014-2016	Academic House Host – Augusta PGY3 students
2014-2016	Chair, Clinical Tracks Work Group
2010- 2012	UGA Faculty alternative delegate for American Association of Colleges of Pharmacy (AACP)
2009-2013	Member, Scholarship and Awards Committee 2012-2013 Chair
2007-2009	Member, Faculty Development Committee
2006-2009	Admissions Committee

---

Augusta University (formerly known as -Georgia Regents University (GRU)

2012-2017	Member, Cancer Institutional Review Board (C-IRB)
2012-2017	Associate Member GRU Cancer Center
2008-2017	GRU/UGA Pharmacy Residency Advisory Committee (RAC) member
2006-2017	GRU BMT/Hematologic Malignancies Committee
2005-2017	GRU Oncology Pharmacy and Therapeutics Subcommittee
2005-2006	Medical College of Georgia (now GHSU) Palliative Care Committee

University of Kentucky

2003-2005	UK Oncology Pharmacy and Therapeutics Subcommittee
2003-2004	UK Medical Center Medication Use Evaluation Subcommittee
2002-2003	UK College of Pharmacy Admissions Committee (Resident member)

**PROFESSIONAL ACTIVITY**

2017- present	American Society of Clinical Oncology (ASCO) member
2015-present	National Community Oncology Dispensing Association (NCODA) <ul style="list-style-type: none"><li>○ Executive Advisory Board</li></ul>
2006-present	Georgia Health Systems Pharmacy (GSHP) member
2006-present	Hematology/Oncology Pharmacy Association (HOPA) member <ul style="list-style-type: none"><li>○ Vice-Chair, Tools and Resources Committee 2017</li><li>○ Board of Directors, Member at Large (2015- 2017)<ul style="list-style-type: none"><li>▪ Advocacy HOPA On the Hill Day Washington, DC 2015, 2016, 2017</li><li>▪ Committee Restructuring Task Force 2016</li><li>▪ Board Liaison, Practice Management (2016-2017)</li><li>▪ Board Liaison, Annual Program Committee (2016-2017)</li><li>▪ Board Liaison, Membership Committee (2015-2016)</li><li>▪ Board Liaison, Publications Committee (2015- 2016)</li><li>▪ BIG idea Taskforce (2015-current)</li></ul></li><li>○ Recognition Committee, Vice Chair (2014- current)</li><li>○ Research and Abstract Review Committee (2010-2013)</li><li>○ Poster Reviewer (2009-2012)</li></ul>
2002-present	American College of Clinical Pharmacy (ACCP) Associate member <ul style="list-style-type: none"><li>○ Research Committee, member (2015-current)</li><li>○ Hematology/Oncology PRN Chair (2015-2016)</li><li>○ Hematology/Oncology PRN Chair Elect (2014-2015)</li><li>○ Hematology/Oncology PRN program committee (2014-current)</li><li>○ Academy Resident Mentor participant (2013- current)</li></ul>

- Mentee – Julianne Orr, Pharm.D. (PGY1 Resident, Greenville Health System)
- Mentee- Sarah Hayes, Pharm.D. (PGY1 Resident, N. Memorial Medical Center)
- Mentee- Deeter Neuman, Pharm.D. (PGY1 Resident, University of Michigan)
- Mentee – Manuel Cortez, Pharm.D. (PGY2 Oncology Resident, University of Chicago)
- Student CV Reviewer (2012- current)
- Student Trivia Game Writer – Oncology (2010-2011) and (2016-2017)
- Hematology/Oncology PRN Member (2003- current)

2012-2014	American Society for Blood and Marrow Transplantation – Affiliate member
2005-2007	ASCO member
2002-2005	Kentucky Health System Pharmacists (KSHP) member
2001-present	American Society of Health System Pharmacists (ASHP)
1998-2002	Kappa Psi Pharmaceutical Fraternity

**CONSULTING**

2013-2016	Merck – Speakers bureau
2010-2012	Georgia Department of Public Health - Georgia Cancer State Aid Program Formulary Reviewer

**SCIENTIFIC JOURNAL REFEREE AND BOOK REVIEWER**

Books

Pharmacotherapy Principles and Practice -3<sup>rd</sup> edition  
 Chapter- *Malignant Lymphomas*

Journals

2017-present	<i>Journal of Pharmacy Technology</i>
2016-present	<i>BMJ Open</i>
2014-present	<i>Journal of Hematology/Oncology Pharmacy</i>
2013-present	<i>Annals of Pharmacotherapy</i>
2013-present	<i>Pharmacotherapy</i>
2012-present	<i>American Journal of Health Systems Pharmacists</i>

**EDITORIAL ACTIVITY**



---

Computer Apps for Oncology Professionals

2014- 2016                      Essential oncology/McMahon Publishing

**COMMUNITY SERVICE**

2013-2017                      Upward Sports Coach (Soccer, Basketball)

2009-2017                      Leukemia and Lymphoma Society – Light the Night fundraising GRU  
team member

2003-2005                      Life Adventure Camp

1998-2002                      Faith Pharmacy Volunteer

1992-1996                      King of the Bluegrass Flag Football Tournament for Big Brothers/Big  
Sisters